Loss of SETD2 is associated with chemoresistance in MLLr leukemia, acute lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML). The gene discussed is SETD2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.